
Choisissez votre étiquette
affichée directement sur le flaconReta + Tesamorelin Blend
GLP-1
- Expédié depuis l'Allemagne
Commande
- DHL avec suivi
- Emballage discret
En un coup d'œil
Reta + Tesamorelin Blend en chiffres
Les chiffres clés de notre lexique.
Article complet du lexique- Type
- Injectable blendtriple agonist + GHRH analog
- Sizes
- 20 mg1 size in the shop
What studies show
All 4 sources in the lexiconRetatrutide phase 2 trial (obesity), 48 weeks, NEJM 2023 (opens in a new tab)
New England Journal of Medicine (PubMed PMID 37366315)Retatrutide systematic review + meta-analysis (878 patients), 2025 (opens in a new tab)
Proc (Bayl Univ Med Cent) (PubMed PMID 40291085)Tesamorelin phase 3 trial (visceral fat, HIV), 12 months (opens in a new tab)
J Acquir Immune Defic Syndr (PubMed PMID 20101189)
Avis
Ce que disent les clients
Uniquement des commandes réelles qui contenaient Reta + Tesamorelin Blend.
Tous les avisIl n'existe pas encore d'analyse de laboratoire pour Reta + Tesamorelin Blend. Votez pourFaites-le tester vous-même, nous payons la moitiéToutes les analyses de laboratoire
Connaissances
Tout sur Reta + Tesamorelin Blend
Informations détaillées bientôt disponibles.
Dosage
Chargement des informations de dosage …
Bon à avoir
Ce dont vous avez besoin avec
L'eau bactériostatique est ajoutée automatiquement à votre panier. Seringues et tampons en un clic.
Seringues à insuline
10 pièces · 5.50 €
Tampons alcoolisés
50 pièces · 10 €
Combien d'eau ?
Unités sur la seringue pour la taille de votre flacon.
Ouvrir le calculateur →Is the Reta + Tesamorelin Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and tesamorelin together. Tesamorelin alone has been approved in the USA since 2010, Retatrutide is in phase 3 and not approved.
What is the catch with the fixed mix?
The two substances were studied on very different schedules: Retatrutide once a week, tesamorelin daily. In a 1:1 vial the ranges from both trial programmes cannot be matched at the same time. The entry therefore goes by the Retatrutide share.
What do the Retatrutide trials show?
In phase 2 body weight fell by 24.2 percent after 48 weeks at the highest study dose, by 2.1 percent on placebo. In phase 3 (TRIUMPH-1) it was 25.0 versus 3.9 percent after 80 weeks. A meta-analysis with 878 participants confirmed clear effects on weight and metabolic values.
What do the tesamorelin trials show?
In 806 patients with HIV and excess belly fat, visceral fat fell by 15.4 percent more than on placebo in 26 weeks, subcutaneous fat stayed nearly the same. IGF-1 rose, blood sugar stayed stable. Those who continued kept the effect to week 52.
Which side effects were seen with the components?
Retatrutide: mainly nausea, diarrhoea and other gastrointestinal effects, depending on the dose, plus a slight rise in heart rate. Tesamorelin: injection site reactions, joint and muscle pain, fluid retention and tingling. There is no safety profile for the blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The phase 3 trials of tesamorelin were completed years ago. No trial of the blend is listed in the registry.
Produits associés
Produits similaires
Tirzepatide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
10 tailles
Testé en laboratoire
= dès 10 €/fiole
Retatrutide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
11 tailles
Testé en laboratoire
= dès 16 €/fiole
Semaglutide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
6 tailles
Testé en laboratoire
= dès 10 €/fiole
Mazdutide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
2 tailles
= dès 32 €/fiole
Reta + Tesamorelin Blend